About this Event
130 Desoto Street, Pittsburgh, 15261
Susan Slaugenhaupt, PhD
Professor of Neurology (Genetics), Harvard Medical School
Investigator, Center for Genomic Medicine
Elizabeth G. Riley and Daniel E. Smith, Jr. Endowed MGH Research Institute Chair
Developing drugs to target RNA splice mutations
Familial dysautonomia (FD), or hereditary sensory and autonomic neuropathy type III, is a rare peripheral neuropathy that is caused by a mutation that disrupts ELP1 RNA splicing. We initially discovered that the plant cytokinin kinetin was a potent modulator of ELP1 splicing, and have since worked to bring a splicing modulator compound (SMC) to the clinic to treat FD patients. After years of optimization, we are completing IND-enabling studies that will hopefully lead to a clinical trial. During my talk I will detail the clinical background of FD, our drug development work, and will discuss the ups and downs of doing this type of work in an academic setting.
Please let us know if you require an accommodation in order to participate in this event. Accommodations may include live captioning, ASL interpreters, and/or captioned media and accessible documents from recorded events. At least 5 days in advance is recommended.